Menu

The latest in stroke research

April 18 - 18, 2018
Ian Potter Auditorium, Florey Institute, 30 Royal Parade (corner Genetics Lane) Parkville VIC 3052

6:00pm on 18 April 2018

Ian Potter Auditorium, Florey Institute 

Register here

Just a few months after the first Mobile Stroke Unit (MSU) hit the streets of Melbourne, two of Australia's most eminent neurologists, Professor Geoffrey Donnan AO and Professor Stephen Davis AO, discuss stroke treatment from a global perspective. 

An estimated one in six people will suffer a stroke in their lifetime. In 2014, 2,954 Victorians died from the disease.  It is the leading cause of disability in Australia, and causes more deaths than breast cancer in women and prostate cancer in men.

Join us to discover how Australia stacks up to other countries in pioneering stroke research. 

Presenters

Professor Geoffrey Donnan AO, MBBS MD FRACP FRCP (Edin) FAHMS

Director of The Florey Institute of Neuroscience and Mental Health and Professor of Neurology, The University of Melbourne.  His major interests are in neuroimaging and clinical trials.  He was co-founder of the Australian Stroke Trials Network (ASTN) and Neuroscience Trials Australia (NTA). He is Past-President of the World Stroke Organization.  He received the American Stroke Association William Feinberg Award for Excellence in Clinical Stroke Research in 2007, the Swedish Karolinska Institute Award for Excellence in Stroke Research and the World Stroke Organization Leadership in Stroke Medicine Award in 2012 and the European Stroke Congress Wepfer Award for stroke research in 2014.

Professor Stephen Davis AO

Professor Davis is the Director of the Melbourne Brain Centre at The Royal Melbourne Hospital. He is the inaugural Professor of Translational Neuroscience at the University of Melbourne. At RMH, he is Director of Neurosciences and Continuing Care at RMH and Director of Neurology. 

In 2012, he was appointed President of the World Stroke Organization. He is the Co-Chair, with Professor Geoffrey Donnan, of Neuroscience Trials Australia (NTA) and has been a trustee of The Royal Melbourne Hospital Neuroscience Foundation since its formation in 1992. 

He is a Consulting Editor for Stroke and Associate Editor for Cerebrovascular Diseases. His major research interests involve clinical trials in stroke and the use of neuroimaging, particularly multimodal MRI, in the selection of acute stroke treatments.